These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33953579)

  • 1. Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.
    Rodriguez-Sanchez B; Aranda-Reneo I; Oliva-Moreno J; Lopez-Bastida J
    Clinicoecon Outcomes Res; 2021; 13():307-334. PubMed ID: 33953579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.
    Rodríguez-Sánchez B; Daugbjerg S; Peña-Longobardo LM; Oliva-Moreno J; Aranda-Reneo I; Cicchetti A; López-Bastida J
    Eur J Health Econ; 2023 Mar; 24(2):247-277. PubMed ID: 35596098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis.
    Aranda-Reneo I; Rodríguez-Sánchez B; Peña-Longobardo LM; Oliva-Moreno J; López-Bastida J
    Value Health; 2021 Mar; 24(3):431-442. PubMed ID: 33641778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How relevant are social costs in economic evaluations? The case of Alzheimer's disease.
    Peña-Longobardo LM; Rodríguez-Sánchez B; Oliva-Moreno J; Aranda-Reneo I; López-Bastida J
    Eur J Health Econ; 2019 Nov; 20(8):1207-1236. PubMed ID: 31342208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considering the societal perspective in economic evaluations: a systematic review in the case of depression.
    Duevel JA; Hasemann L; Peña-Longobardo LM; Rodríguez-Sánchez B; Aranda-Reneo I; Oliva-Moreno J; López-Bastida J; Greiner W
    Health Econ Rev; 2020 Sep; 10(1):32. PubMed ID: 32964372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.
    Schnitzler L; Evers SMAA; Jackson LJ; Paulus ATG; Roberts TE
    BMC Public Health; 2022 Nov; 22(1):2180. PubMed ID: 36434561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review.
    Kigozi J; Jowett S; Lewis M; Barton P; Coast J
    Value Health; 2017 Mar; 20(3):496-506. PubMed ID: 28292496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.
    Krol M; Papenburg J; van Exel J
    Pharmacoeconomics; 2015 Feb; 33(2):123-35. PubMed ID: 25315368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cost of schizophrenia: a literature review].
    Charrier N; Chevreul K; Durand-Zaleski I
    Encephale; 2013 May; 39 Suppl 1():S49-56. PubMed ID: 23351935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scope of costs in alcohol studies: Cost-of-illness studies differ from economic evaluations.
    van Gils PF; Hamberg-van Reenen HH; van den Berg M; Tariq L; de Wit GA
    Cost Eff Resour Alloc; 2010 Jul; 8():15. PubMed ID: 20602804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CONCEPTUALIZATIONS OF THE SOCIETAL PERSPECTIVE WITHIN ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW.
    Drost RMWA; van der Putten IM; Ruwaard D; Evers SMAA; Paulus ATG
    Int J Technol Assess Health Care; 2017 Jan; 33(2):251-260. PubMed ID: 28641592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Productivity costs in economic evaluations: past, present, future.
    Krol M; Brouwer W; Rutten F
    Pharmacoeconomics; 2013 Jul; 31(7):537-49. PubMed ID: 23620213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.
    Krol M; Papenburg J; Koopmanschap M; Brouwer W
    Pharmacoeconomics; 2011 Jul; 29(7):601-19. PubMed ID: 21545189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines.
    Silver MC; Neumann PJ; Ma S; Kim DD; Cohen JT; Nyaku M; Roberts C; Sinha A; Ollendorf DA
    Vaccine; 2021 Nov; 39(46):6727-6734. PubMed ID: 34656380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries.
    Schrappe M; Lauterbach K
    AIDS; 1998; 12 Suppl A():S231-8. PubMed ID: 9633007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and quality assessment of economic evaluation studies of injury prevention.
    Polinder S; Segui-Gomez M; Toet H; Belt E; Sethi D; Racioppi F; van Beeck EF
    Accid Anal Prev; 2012 Mar; 45():211-21. PubMed ID: 22269503
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.